Business Context and Reporting Period
This Form 8-K filing by SS Innovations International, Inc. (SSi) reports a significant financing event dated December 4, 2024, with the report signed on January 24, 2025. The company is incorporated in Florida and operates without securities registered on a national exchange.
Key Financial Metrics
The filing details a series of financing transactions rather than operational financial results. Key metrics include:
- Total Financing Committed: $17.0 million in aggregate principal amount.
- Tranche 1: $2.0 million received on December 4, 2024.
- Tranche 2: $5.0 million received on January 3, 2025.
- Tranche 3: $10.0 million received on January 20, 2025.
- Interest Rate: 7% per annum, accruing and due at maturity.
- Conversion Price: $1.38 per share.
- Maturity: One year from issuance.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels outside of these new notes.
Material Changes
The primary material change is the injection of capital through convertible promissory notes issued to Sushruta Pvt Ltd., a Bahamian holding company controlled by Dr. Sudhir Srivastava, the Company's Chairman and CEO. This represents a shift in the company's capital structure to support capacity expansion and working capital needs for 2025.
Guidance, Outlook, and Risks
Management Commentary: Dr. Srivastava has advised the Company of his intent to provide an undetermined amount of additional financing in 2025 to support business expansion.
Terms and Conditions: The notes are convertible at the holder's option at maturity or upon the completion of a "Qualified Sale." The conversion price is subject to adjustment for stock splits or dividends.
Risks and Contingencies: The financing was issued under Section 4(a)(2) and Rule 506(b) exemptions, relying on the investor's status as an accredited investor. The company faces potential dilution if the notes are converted at the $1.38 per share price.
Investor Verification Checklist
- Verify the exact closing dates and receipt of funds for the January 3, 2025, and January 20, 2025, tranches.
- Confirm the definition of a "Qualified Sale" in the One-Year Notes to understand potential early conversion triggers.
- Assess the impact of potential conversion at $1.38 per share on current shareholder equity.
- Monitor for announcements regarding the "undetermined amount" of additional financing mentioned for 2025.
- Review the company's latest audited financial statements to understand the baseline liquidity prior to this $17.0 million injection.